BESPONSA® (inotuzumab ozogamicin) Dosing & Administration |Safety Info

Patients not proceeding to HSCT¹	Patients proceeding to HSCT¹
Up to a maximum of 6 cycles may be administered	The recommended duration of treatment with BESPONSA is 2 cycles A third cycle may be considered for those patients who do not achieve CR/CRi and MRD negativity after 2 cycles

Patients not proceeding to HSCT¹

Patients proceeding to HSCT¹

Up to a maximum of 6 cycles may be administered

The recommended duration of treatment with BESPONSA is 2 cycles
A third cycle may be considered for those patients who do not achieve CR/CRi and MRD negativity after 2 cycles

Hematologic toxicities
If prior to BESPONSA treatment ANC was ≥1 × 10⁹/L	If ANC decreases, then interrupt the next cycle of treatment until recovery of ANC to ≥1 × 10⁹/L Discontinue BESPONSA if low ANC persists for >28 days and is suspected to be related to BESPONSA
If prior to BESPONSA treatment platelet count was ≥50 × 10⁹/L*	If platelet count decreases, then interrupt the next cycle of treatment until platelet count recovers to ≥50 × 10⁹/L* Discontinue BESPONSA if low platelet count persists for >28 days and is suspected to be related to BESPONSA
If prior to BESPONSA treatment ANC was <1 × 10⁹/L and/or platelet count was <50 × 10⁹/L*	If ANC or platelet count decreases, then interrupt the next cycle of treatment until at least one of the following occurs: ANC and platelet counts recover to at least baseline levels for the prior cycle, or ANC recovers to ≥1 × 10⁹/L and platelet count recovers to ≥50 × 10⁹/L* or Stable or improved disease (based on most recent bone marrow assessment) and ANC and platelet count decrease is considered to be due to the underlying disease (not considered to be related to BESPONSA)

Hematologic toxicities

Criteria

Dose modification(s)

If prior to BESPONSA treatment ANC was
≥1 × 10⁹/L

If ANC decreases, then interrupt the next cycle of treatment until recovery of ANC to ≥1 × 10⁹/L

Discontinue BESPONSA if low ANC persists for >28 days and is suspected to be related to BESPONSA

If prior to BESPONSA treatment platelet count was ≥50 × 10⁹/L*

If platelet count decreases, then interrupt the next cycle of treatment until platelet count recovers to ≥50 × 10⁹/L*

Discontinue BESPONSA if low platelet count persists for >28 days and is suspected to be related to BESPONSA

If prior to BESPONSA treatment ANC was <1 × 10⁹/L and/or platelet count was <50 × 10⁹/L*

If ANC or platelet count decreases, then interrupt the next cycle of treatment until at least one of the following occurs:

ANC and platelet counts recover to at least baseline levels for the prior cycle, or
ANC recovers to ≥1 × 10⁹/L and platelet count recovers to ≥50 × 10⁹/L* or
Stable or improved disease (based on most recent bone marrow assessment) and ANC and platelet count decrease is considered to be due to the underlying disease (not considered to be related to BESPONSA)

Nonhematologic toxicities
VOD or other severe liver toxicity	Permanently discontinue treatment
Total bilirubin >1.5 × ULN and AST/ALT >2.5 × ULN	Interrupt dosing until recovery of total bilirubin to ≤1.5 × ULN and AST/ALT to ≤2.5 × ULN prior to each dose, unless due to Gilbert’s syndrome or hemolysis. Permanently discontinue treatment if total bilirubin does not recover to ≤1.5 × ULN or AST/ALT does not recover to ≤2.5 × ULN
Infusion-related reaction	Interrupt the infusion and institute appropriate medical management Depending on the severity of the infusion-related reaction, consider discontinuation of the infusion or administration of steroids and antihistamines For severe or life-threatening infusion-related reactions, permanently discontinue treatment
Nonhematologic toxicity Grade ≥2^†	Interrupt treatment until recovery to Grade 1 or pretreatment grade levels prior to each dose

Nonhematologic toxicities

Nonhematologic toxicity

Dose modification(s)

VOD or other severe liver toxicity

Permanently discontinue treatment

Total bilirubin >1.5 × ULN and AST/ALT >2.5 × ULN

Interrupt dosing until recovery of total bilirubin to ≤1.5 × ULN and AST/ALT to ≤2.5 × ULN prior to each dose, unless due to Gilbert’s syndrome or hemolysis. Permanently discontinue treatment if total bilirubin does not recover to ≤1.5 × ULN or AST/ALT does not recover to ≤2.5 × ULN

Infusion-related reaction

Interrupt the infusion and institute appropriate medical management

Depending on the severity of the infusion-related reaction, consider discontinuation of the infusion or administration of steroids and antihistamines
For severe or life-threatening infusion-related reactions, permanently discontinue treatment

Nonhematologic toxicity Grade ≥2^†

Interrupt treatment until recovery to Grade 1 or pretreatment grade levels prior to each dose

Important Safety Information

WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST–HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY (NRM):

Hepatotoxicity, including fatal and life-threatening VOD, occurred in patients who received BESPONSA. The risk of VOD was greater in patients who underwent HSCT after BESPONSA treatment. The use of HSCT conditioning regimens containing 2 alkylating agents and last total bilirubin ≥ upper limit of normal (ULN) before HSCT were significantly associated with an increased risk of VOD
Other risk factors for VOD in patients treated with BESPONSA included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of BESPONSA treatment cycles
Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA. Permanently discontinue treatment if VOD occurs. If severe VOD occurs, treat according to standard medical practice
There was a higher post-HSCT non-relapse mortality rate in patients receiving BESPONSA, resulting in a higher Day 100 post-HSCT mortality rate

Hepatotoxicity, Including Hepatic VOD: Hepatotoxicity, including fatal and life-threatening VOD, occurred in 23/164 patients (14%) during or following treatment with BESPONSA or following subsequent HSCT. VOD was reported up to 56 days after the last dose during treatment or follow-up without an intervening HSCT. The median time from HSCT to onset of VOD was 15 days.

Patients with prior VOD or serious ongoing liver disease are at an increased risk of worsening liver disease, including development of VOD, following treatment with BESPONSA. Monitor closely for signs and symptoms of VOD; these may include elevations in total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. For patients proceeding to HSCT, the recommended duration of treatment with BESPONSA is 2 cycles. A third cycle may be considered for patients who do not achieve a CR or CRi and MRD-negativity after 2 cycles. Monitor liver tests closely during the first month post HSCT, then less frequently thereafter, according to standard medical practice.

Grade 3/4 increases in aspartate aminotransferase, alanine aminotransferase, and total bilirubin occurred in 7/160 (4%), 7/161 (4%), and 8/161 (5%) patients, respectively.

Increased Risk of Post-HSCT Non-Relapse Mortality (NRM): There was a higher post-HSCT NRM rate in patients receiving BESPONSA, resulting in a higher Day 100 post-HSCT mortality rate. The rate of post-HSCT NRM was 31/79 (39%) with BESPONSA and 8/35 (23%) with investigator’s choice of chemotherapy. In the BESPONSA arm, the most common causes of post-HSCT NRM included VOD and infections. Monitor closely for toxicities post HSCT, including signs and symptoms of infection and VOD.

Myelosuppression: Myelosuppression, and severe, life-threatening, and fatal complications of myelosuppression, including hemorrhagic events and infections, have occurred with BESPONSA. Thrombocytopenia and neutropenia were reported in 83/164 patients (51%) and 81/164 patients (49%), respectively. Febrile neutropenia was reported in 43/164 patients (26%).

Monitor complete blood counts prior to each dose of BESPONSA and monitor for signs and symptoms of infection, bleeding/hemorrhage, or other effects of myelosuppression during treatment and provide appropriate management. As appropriate, administer prophylactic anti-infectives during and after treatment with BESPONSA. Dose interruption, dose reduction, or permanent discontinuation may be required.

Infusion-Related Reactions: Infusion-related reactions (all Grade 2) were reported in 4/164 patients (2%). Premedicate with a corticosteroid, antipyretic, and antihistamine prior to dosing. Monitor patients closely during and for at least 1 hour after the end of the infusion for the potential onset of infusion-related reactions including symptoms such as fever, chills, rash, or breathing problems. Interrupt the infusion and institute appropriate medical management if an infusion-related reaction occurs. Depending on the severity, consider discontinuation of the infusion or administration of steroids and antihistamines. For severe or life-threatening infusion reactions, permanently discontinue BESPONSA.

QT Interval Prolongation: Increases in QT interval corrected for heart rate using Fridericia’s formula of ≥60 msec from baseline were measured in 4/162 patients (3%). Administer BESPONSA with caution in patients who have a history of or predisposition to QTc prolongation, who are taking medicinal products that are known to prolong QT interval, and in patients with electrolyte disturbances. Obtain electrocardiograms and electrolytes prior to treatment and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

Embryo-Fetal Toxicity: BESPONSA can cause embryo-fetal harm. Apprise pregnant women of the potential risk to the fetus. Advise males and females of reproductive potential to use effective contraception during BESPONSA treatment and for at least 5 and 8 months after the last dose, respectively. Advise women to contact their healthcare provider if they become pregnant or if pregnancy is suspected during treatment with BESPONSA.

Adverse Reactions: The most common (≥20%) adverse reactions observed with BESPONSA were thrombocytopenia, neutropenia, infection, anemia, leukopenia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, transaminases increased, abdominal pain, gamma-glutamyltransferase increased, and hyperbilirubinemia. The most common (≥2%) serious adverse reactions were infection, febrile neutropenia, hemorrhage, abdominal pain, pyrexia, VOD, and fatigue.

Nursing Mothers: Advise women against breastfeeding while receiving BESPONSA and for 2 months after the last dose.

INDICATION

BESPONSA® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Please see full Prescribing Information, including BOXED WARNING.